Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Bronchodilators Market: By Drug Class, By Route of Administration, By Disease Type, Others), By Distribution Channel, and Geography
Bronchodilators market size was valued at US$ 34.6 billion in 2023 and is poised to grow at a CAGR of 5.4% from 2024-2030. The global market provides a detailed overview of the global bronchodilators market, and that can be segmented by drug class, route of administration, disease type, and distribution channel. By drug class, the global bronchodilators market has been segmented into Phosphodiesterase Inhibitors, Anticholinergics, Sympathomimetics, and Combination Drugs.
The Anticholinergics Inhibitors segment is likely to be the largest and fastest-growing segment in terms of drug class in 2021 and is expected to maintain the trend in the forecasted years. It is attributed to its wide application to treat chronic obstructive pulmonary disease. Based on route of administration, the global bronchodilators market is segmented into Oral Care Products, Parenteral, and Inhalation.
Among these, the Oral segment is expected to have the fastest-growing market during the forecast period 2024-2030. Based on disease type, the global bronchodilators market is segmented into Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Others. The Asthma segment accounts for the largest share in 2021. Hosted segment is the second-largest share during the forecast period. period according to precision business insights. It is attributed to the increasing prevalence of asthma across the world. Based on distribution channel, the global bronchodilators market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.
Hospital Pharmacies segment accounts for the largest share in 2023. Hospital pharmacies has very large patient base and prescribed medicines for hospital patients are boosting the growth in this segment. Bronchodilators are agents dilate the bronchioles and bronchi to improve the airflow to the lungs. These are commonly used in the treatment of obstructive lung diseases such as chronic obstructive pulmonary disease (COPD) emphysema, asthma, and other lung diseases. Bronchodilators are majorly classified based on their duration of action such as short-acting and long-acting.
Study Period
2024-2030Base Year
2023CAGR
5.4%Largest Market
North AmericaFastest Growing Market
Europe
Increase in the aging population coupled with rise in prevalence of various lung diseases such as asthma and COPD are anticipated to propel the market growth over the forecast years.
Report Benchmarks |
Details |
Report Study Period |
2024-2030 |
Market Size in 2023 |
US$ 34.6 billion |
Market CAGR |
5.4% |
By Drug Class |
|
By Administration |
|
By Disease Type |
|
By Distribution Channel |
|
Download Free Sample Report
The bronchodilators market size was valued at US$ 34.6 billion in 2023
The bronchodilators market key players are: Hoffmann La Roche Ltd. (Switzerland) Boehringer Ingelheim GmbH (Germany) Novartis AG (Switzerland) Merck & Co. Inc. (U.S.) AstraZeneca plc (U.K.) GlaxoSmithKline (U.S.) Aquinox Pharmaceuticals (Canada) MediciNova, Inc. (U.S.) Gilead Sciences, Inc. (U.S.) Biomarck Pharmaceuticals (U.S.)
The slam technology market bronchodilators market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
1. Executive Summary |
2. Global Bronchodilators Market Introduction |
2.1.Global Bronchodilators Market - Taxonomy |
2.2.Global Bronchodilators Market - Definitions |
2.2.1.Drug Class |
2.2.2.Administration |
2.2.3.Disease Type |
2.2.4.Distribution Channel |
2.2.5.Region |
3. Global Bronchodilators Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4. Global Bronchodilators Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Bronchodilators Market By Drug Class, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
5.1. Phosphodiesterase Inhibitors |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Anticholinergics |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Sympathomimetics |
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Non-Selective Adrenergic Agonists |
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Non-Selective Beta-2 Agonists |
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
5.6. Selective Beta-2 Agonists |
5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.6.3. Market Opportunity Analysis |
5.7. Combination Drugs |
5.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.7.3. Market Opportunity Analysis |
6. Global Bronchodilators Market By Administration, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
6.1. Oral |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Parenteral |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Inhalation |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
7. Global Bronchodilators Market By Disease Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
7.1. Asthma |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Chronic Obstructive Pulmonary Disease (COPD) |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Others |
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8. Global Bronchodilators Market By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
8.1. Hospital Pharmacies |
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Retail Pharmacies |
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Online Pharmacies |
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
9. Global Bronchodilators Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
9.1. North America |
9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.1.3. Market Opportunity Analysis |
9.2. Europe |
9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.2.3. Market Opportunity Analysis |
9.3. Asia Pacific (APAC) |
9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.3.3. Market Opportunity Analysis |
9.4. Middle East and Africa (MEA) |
9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.4.3. Market Opportunity Analysis |
9.5. Latin America |
9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.5.3. Market Opportunity Analysis |
10. North America Bronchodilators Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
10.1. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Phosphodiesterase Inhibitors |
10.1.2.Anticholinergics |
10.1.3.Sympathomimetics |
10.1.4.Non-Selective Adrenergic Agonists |
10.1.5.Non-Selective Beta-2 Agonists |
10.1.6.Selective Beta-2 Agonists |
10.1.7.Combination Drugs |
10.2. Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Oral |
10.2.2.Parenteral |
10.2.3.Inhalation |
10.3. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Asthma |
10.3.2.Chronic Obstructive Pulmonary Disease (COPD) |
10.3.3.Others |
10.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Hospital Pharmacies |
10.4.2.Retail Pharmacies |
10.4.3.Online Pharmacies |
10.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.5.1.United States of America (USA) |
10.5.2.Canada |
11. Europe Bronchodilators Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
11.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Phosphodiesterase Inhibitors |
11.1.2.Anticholinergics |
11.1.3.Sympathomimetics |
11.1.4.Non-Selective Adrenergic Agonists |
11.1.5.Non-Selective Beta-2 Agonists |
11.1.6.Selective Beta-2 Agonists |
11.1.7.Combination Drugs |
11.2. Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Oral |
11.2.2.Parenteral |
11.2.3.Inhalation |
11.3. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Asthma |
11.3.2.Chronic Obstructive Pulmonary Disease (COPD) |
11.3.3.Others |
11.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.Hospital Pharmacies |
11.4.2.Retail Pharmacies |
11.4.3.Online Pharmacies |
11.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.5.1.Germany |
11.5.2.France |
11.5.3.Italy |
11.5.4.United Kingdom (UK) |
11.5.5.Spain |
11.5.6.Rest of EU |
12. Asia Pacific (APAC) Bronchodilators Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
12.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Phosphodiesterase Inhibitors |
12.1.2.Anticholinergics |
12.1.3.Sympathomimetics |
12.1.4.Non-Selective Adrenergic Agonists |
12.1.5.Non-Selective Beta-2 Agonists |
12.1.6.Selective Beta-2 Agonists |
12.1.7.Combination Drugs |
12.2. Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Oral |
12.2.2.Parenteral |
12.2.3.Inhalation |
12.3. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Asthma |
12.3.2.Chronic Obstructive Pulmonary Disease (COPD) |
12.3.3.Others |
12.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.Hospital Pharmacies |
12.4.2.Retail Pharmacies |
12.4.3.Online Pharmacies |
12.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.5.1.China |
12.5.2.India |
12.5.3.Australia and New Zealand (ANZ) |
12.5.4.Japan |
12.5.5.Rest of APAC |
13.Middle East and Africa (MEA) Bronchodilators Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
13.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Phosphodiesterase Inhibitors |
13.1.2.Anticholinergics |
13.1.3.Sympathomimetics |
13.1.4.Non-Selective Adrenergic Agonists |
13.1.5.Non-Selective Beta-2 Agonists |
13.1.6.Selective Beta-2 Agonists |
13.1.7.Combination Drugs |
13.2. Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Oral |
13.2.2.Parenteral |
13.2.3.Inhalation |
13.3. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Asthma |
13.3.2.Chronic Obstructive Pulmonary Disease (COPD) |
13.3.3.Others |
13.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Hospital Pharmacies |
13.4.2.Retail Pharmacies |
13.4.3.Online Pharmacies |
13.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.5.1.GCC Countries |
13.5.2.South Africa |
13.5.3.Rest of MEA |
14.Latin America Bronchodilators Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
14.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.1.1.Phosphodiesterase Inhibitors |
14.1.2.Anticholinergics |
14.1.3.Sympathomimetics |
14.1.4.Non-Selective Adrenergic Agonists |
14.1.5.Non-Selective Beta-2 Agonists |
14.1.6.Selective Beta-2 Agonists |
14.1.7.Combination Drugs |
14.2. Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.2.1.Oral |
14.2.2.Parenteral |
14.2.3.Inhalation |
14.3. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.3.1.Asthma |
14.3.2.Chronic Obstructive Pulmonary Disease (COPD) |
14.3.3.Others |
14.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.4.1.Hospital Pharmacies |
14.4.2.Retail Pharmacies |
14.4.3.Online Pharmacies |
14.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.5.1.Brazil |
14.5.2.Mexico |
14.5.3.Rest of LA |
15. Competition Landscape |
15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
15.2.1.Hoffmann La Roche Ltd. (Switzerland) |
15.2.2.Boehringer Ingelheim GmbH (Germany) |
15.2.3.Novartis AG (Switzerland) |
15.2.4.Merck & Co. Inc. (U.S.) |
15.2.5.AstraZeneca plc (U.K.) |
15.2.6.GlaxoSmithKline (U.S.) |
15.2.7.Aquinox Pharmaceuticals (Canada) |
15.2.8.MediciNova, Inc. (U.S.) |
15.2.9.Gilead Sciences, Inc. (U.S.) |
15.2.10.Biomarck Pharmaceuticals (U.S.) |
16. Research Methodology |
17. Appendix and Abbreviations |
Key Market Players